Mayo Clinic Proceedings - Symposium on Neoplastic Hematology and Medical Oncology - Multiple Myeloma: Diagnosis and Treatment (January 1, 2016)
One of the premier peer-reviewed clinical journals in general and internal medicine, Mayo Clinic Proceedings is among the most widely read and highly cited scientific publications for physicians, with a circulation of approximately 125,000. Mayo Clinic Proceedings is published by Elsevier and sponsored by Mayo Clinic and the Mayo Foundation for Medical Education and Research. The mission of Mayo Clinic Proceedings is to promote the best interest of patients by advancing the knowledge and professionalism of the physician community. Since 2009 the Journal has offered CME credit for specific articles from both the Mayo Clinic for Concise Review for Clinicians and specially commissioned Symposia articles (comprehensive coverage on one topic).
Participation in this activity consists of reviewing articles and responding to a short online test. It is estimated that this activity will take approximately one hour per article. There is no charge for participating in this Journal CME activity.
NOTE: You must select AMA PRA Category 1 CreditTM in your profile's credit eligiblility field in order for the sytem to recognize that you want CME credit. The system will only issue credit for the credit types that match your profile.
To receive CME credit, please do the following:
- Click Take Course
- Complete quiz and evaluation (There is a required 80% pass rate in order to earn credit, with 1 retake allowed.)
- Print your Record of Attendance
Mayo Clinic College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Mayo Clinic College of Medicine designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
William Lanier, M.D., Thomas Beckman, M.D., Christopher M. Wittich, M.D., Terry Jopke, Nicki Smith
S. Vincent Rajkumar, MD, Shaji Kumar, MD
Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota
None of the planning members above have anything to disclose.
Dr. Rajkumar has nothing to disclose.
Dr. Kumar reports grants from Celgene Corp, Millennium, Novartis, Janssen, and Sanofi, outside the submitted work.
Supported in part by grants CA 107476 and CA 168762 from the National Cancer Institute, Rockville, MD, USA.
The following off-label use of the following drugs will be mentioned:
Amgen: Carfilzomib for newly diagnosed myeloma
Bristol Myers Squibb: Elotuzumab for myeloma
Janssen: Daratumumab for myeloma
Takeda: Ixazomib for myeloma
The target audience for Mayo Clinic Proceedings is primarily internal medicine physicians and other clinicians who wish to advance their current knowledge of clinical medicine and who wish to stay abreast of advances in medical research.
On completion of this article, you should be able to (1) list the criteria for diagnosis of multiple myeloma and related disorders, (2) identify high risk prognostic markers for multiple myeloma and smoldering multiple myeloma, and (3) summarize the approach to treatment of multiple myeloma.
- 1.00 ABIM
- 1.00 AMA PRA Category 1 Credit™